These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34057099)

  • 1. Companies' statements about drugs withdrawn from the Canadian market: A descriptive analysis.
    Lexchin J
    Int J Risk Saf Med; 2021; 32(4):331-341. PubMed ID: 34057099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How long do new medicines take to reach Canadian patients after companies file a submission: A cohort study.
    Lexchin J
    PLoS One; 2020; 15(11):e0240966. PubMed ID: 33137156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites.
    Tyrawski J; DeAndrea DC
    J Med Internet Res; 2015 Jun; 17(6):e130. PubMed ID: 26032738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study.
    Lexchin J; Batt S; Goldberg D; Shnier A
    BMJ Open; 2022 Mar; 12(3):e055287. PubMed ID: 35264357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multinational Pharmaceutical Companies Shortchange Canada in Research and Development Investments: Is It Time to Pursue Other Options?
    Lee SK; Mahl SK; Green JJ; Lexchin J
    Healthc Policy; 2023 Feb; 18(3):17-24. PubMed ID: 36917450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond "medical tourism": Canadian companies marketing medical travel.
    Turner L
    Global Health; 2012 Jun; 8():16. PubMed ID: 22703873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices.
    Miller J; Ross JS; Wilenzick M; Mello MM
    BMJ; 2019 Jul; 366():l4217. PubMed ID: 31292127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canadian medical tourism companies that have exited the marketplace: Content analysis of websites used to market transnational medical travel.
    Turner L
    Global Health; 2011 Oct; 7():40. PubMed ID: 21995598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economics in the Canadian pharmaceutical industry.
    Assiff L; Pollock MR; Manzi P; Faienza B; Menon D
    Pharmacoeconomics; 1999 Dec; 16(6):669-78. PubMed ID: 10724794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabis companies and the sponsorship of scientific research: A cross-sectional Canadian case study.
    Grundy Q; Imahori D; Mahajan S; Garner G; Timothy R; Sud A; Soklaridis S; Buchman DZ
    PLoS One; 2023; 18(1):e0280110. PubMed ID: 36626363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to market for drugs approved in Canada between 2014 and 2018: an observational study.
    Lexchin J
    BMJ Open; 2021 Jul; 11(7):e047557. PubMed ID: 34226224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Companies' Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study.
    Wang T; McAuslane N; Liberti L; Gardarsdottir H; Goettsch W; Leufkens H
    Front Pharmacol; 2020; 11():594549. PubMed ID: 33390978
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency.
    Regnstrom J; Koenig F; Aronsson B; Reimer T; Svendsen K; Tsigkos S; Flamion B; Eichler HG; Vamvakas S
    Eur J Clin Pharmacol; 2010 Jan; 66(1):39-48. PubMed ID: 19936724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the nutritional quality of products offered by the top packaged food and beverage companies in Canada.
    Vergeer L; Vanderlee L; Ahmed M; Franco-Arellano B; Mulligan C; Dickinson K; L'Abbé MR
    BMC Public Health; 2020 May; 20(1):650. PubMed ID: 32393206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responsiveness to physicians' requests for information concerning drug interactions: a comparison of brand and generic companies.
    Thomas M; Lexchin J
    Soc Sci Med; 1990; 31(2):153-7. PubMed ID: 2389150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between physicians and the pharmaceutical industry: what does the literature say?
    Lexchin J
    CMAJ; 1993 Nov; 149(10):1401-7. PubMed ID: 8221424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.